Bispecific CARs Targeting CD20 BCMA, AbelZeta, Autoimmune, Cancer
Summary
AbelZeta Inc. filed US Patent Application US20260108557A1 for a bispecific chimeric antigen receptor (CAR) targeting both CD20 and BCMA antigens simultaneously. The CAR construct comprises an scFv targeting CD20 and an scFv targeting BCMA, a hinge region, a transmembrane domain, a co-stimulatory region, and a cytoplasmic signaling domain. The application was filed on October 13, 2025, and published on April 23, 2026, with claims directed to methods of treating autoimmune disorders and cancer using the disclosed CAR.
“The present disclosure provides bispecific chimeric antigen receptors targeting CD20 and BCMA.”
About this source
GovPing monitors USPTO Patent Applications - Therapeutics (A61P) for new healthcare & life sciences regulatory changes. Every update since tracking began is archived, classified, and available as free RSS or email alerts — 203 changes logged to date.
What changed
USPTO published Application US20260108557A1 for a bispecific CAR targeting CD20 and BCMA, filed by AbelZeta Inc. The CAR construct integrates two scFv binding domains (one for each antigen), linked to hinge, transmembrane, co-stimulatory, and cytoplasmic signaling regions, designed for simultaneous dual-antigen targeting.\n\nCompanies developing CAR-T or bispecific immunotherapy programs targeting CD20 (e.g., B-cell lymphomas) or BCMA (e.g., multiple myeloma) should review this filing for potential overlap with their own programs and assess freedom-to-operate implications, particularly for combination approaches that engage both antigens.
Archived snapshot
Apr 23, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
BISPECIFIC CHIMERIC ANTIGEN RECEPTORS TARGETING CD20 AND BCMA
Application US20260108557A1 Kind: A1 Apr 23, 2026
Assignee
ABELZETA INC.
Inventors
Yihong YAO, Jiaqi HUANG, Shigui ZHU, Xin YAO, Xiaobing LUO, Yutian WEI
Abstract
The present disclosure provides bispecific chimeric antigen receptors targeting CD20 and BCMA. The CAR may comprise an scFv targeting CD20 and an scFv targeting BCMA, a hinge region, a transmembrane domain, a co-stimulatory region, and a cytoplasmic signaling domain. The chimeric antigen receptors can be used to treat autoimmune disorders or cancer.
CPC Classifications
A61K 35/17 A61K 40/11 A61K 40/15 A61K 40/31 A61K 40/4202 A61K 40/4215 A61K 40/4221 A61K 40/4224 A61P 35/00 A61P 37/02 A61P 37/06 C07K 16/2878 C07K 16/2887 C12N 5/0636 A61K 2239/13 A61K 2239/21 A61K 2239/22 A61K 2239/29 C07K 2317/31 C07K 2317/53 C07K 2317/622 C07K 2319/03 C12N 2510/00
Filing Date
2025-10-13
Application No.
19356595
Parties
Related changes
Get daily alerts for USPTO Patent Applications - Therapeutics (A61P)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Applications - Therapeutics (A61P) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.